Trial Profile

A randomized phase III study in previously untreated patients with biological high-risk CLL [chronic lymphocytic leukaemia]: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Aug 2023 According to European Clinical Trials Database, the trial is completed in Finland and Czech while its ongoing in Sweden , Denmark and Belgium.
12 Dec 2017 Results (n=187) assessing effect of B-cell receptors stereotypy subsets on the primary outcome presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
14 Jun 2013 Results of an analysis that investigated the effects of genetic mutations on outcomes (n=119) presented at the 18th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com